Fangrong Yan

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial

Jing Pan, Yue Tan, Guoling Wang et al. · Journal of Clinical Oncology · 2021 · 294 citations

Life Sciences, Hematology, Immunology +15

Immune Signature-Based Subtypes of Cervical Squamous Cell Carcinoma Tightly Associated with Human Papillomavirus Type 16 Expression, Molecular Features, and Clinical Outcome

Xiaofan Lu, Liyun Jiang, Liya Zhang et al. · Neoplasia · 2019 · 251 citations · Full text

Medicine, Immunology, Oncology +17

<i>MOVICS</i> : an R package for multi-omics integration and visualization in cancer subtyping

Xiaofan Lu, Jialin Meng, Yujie Zhou et al. · Bioinformatics · 2020 · 222 citations · Full text

Life Sciences, Bioinformatics, Oncology +17

Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials

Fangrong Yan, Sumithra J. Mandrekar, Ying Yuan · Clinical Cancer Research · 2017 · 179 citations · Full text

Public Health, Pharmacology, Dose-response Modeling +14

BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies

Ruitao Lin, Yanhong Zhou, Fangrong Yan et al. · JCO Precision Oncology · 2020 · 144 citations · Full text

Medicine, Biostatistics, Immunology +17